Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by Cantor Fitzgerald to Neutral

Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports. Cantor Fitzgerald currently has $36.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $57.00.

Supernus Pharmaceuticals Trading Down 15.7 %

Shares of NASDAQ:SUPN opened at $33.52 on Wednesday. The firm’s 50 day moving average is $37.58 and its two-hundred day moving average is $35.27. Supernus Pharmaceuticals has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a market capitalization of $1.85 billion, a P/E ratio of 31.33 and a beta of 0.90.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vident Advisory LLC boosted its stake in Supernus Pharmaceuticals by 2.2% in the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after purchasing an additional 309 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the period. Summit Investment Advisors Inc. boosted its stake in Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 369 shares during the period. Bank of Montreal Can boosted its stake in Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 473 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after purchasing an additional 560 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.